"Sample.ID" "sex" "Age" "Sequencing" "sample_ID" "Institution" "Manuscript.ID" "Dx" "DxELN_Cytogenetic" "Cytogenetics" "Overall.survival" "Flow.report.summary" "RAS.pathway" "NPM1" "IDH" "TET2" "TP53" "RUNX1" "CBF" "MLL.rearranged" "IDH1" "IDH2" "ASXL1" "BCOR" "CBL" "CEBPAdm" "CSF3R" "DNMT3A" "ETV6" "FLT3.TKD" "FLT3.ITD" "GATA2" "JAK2" "KIT" "NPM1.1" "NRAS" "KRAS" "PTPN11" "PHF6" "RAD21" "RUNX1.1" "SETBP1" "SMC1A" "STAG2" "SRSF2" "SF3B1" "TET2.1" "U2AF1" "WT1" "TP53.1" "ZRSR2" "health_status" "case_or_control" "nr_cells_raw" "nr_cells_cf" "nr_cells_cf_ctf" "total_counts_raw_cf_ctf_gf" "nr_celltypes_cf_ctf_gf" "threshold_nr_celltypes" "passed_threshold_nr_celltypes" "U-06-0024" "M" 64 "CITE-seq" "AML-0024" "OSU" "AML0024" "AML" "Adverse" "48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)" 137 "" "" "" "" "" "" "" NA NA "0+T2:BL24" "0,46" "0" "0,99" "0" 0 "0" "0" "0" "0,06" "0" "0" "0" "0" "0,17" "0" "0" "0,17" 0 0 "0" 0 0 0 "0" 0 "0" "0,45" "0" "0" "0" "AML" "case" 6141 6127 6127 16080180.1293001 8 "greater or equal 7" TRUE "U-16-0160" "M" 74 "CITE-seq" "AML-0160" "OSU" "AML0160" "AML" "Adverse" "46,XY[30]" 3 "Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+ with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%)." "" "" "" "x" "" "x" NA NA "0" "0" "0,45" "0" "0" 0 "0" "0" "0" "0" "0" "0" "0" "0" "0" "0" "0" "0" 0 0 "0,76" 0 0 0 "0" 0 "0,43" "0" "0" "0" "0" "AML" "case" 2186 2169 2149 4764255.94405791 7 "greater or equal 7" TRUE "U-11-0693" "F" 77 "CITE-seq + scTCR-seq" "AML-0693" "OSU" "AML0693" "AML" "Adverse" "74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)" 47 "Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker).  The immature cells are positive for MPO, CD68 and CD117.  They are negative for the rest stains." "" "" "" "" "x" "" NA NA "" "" "" "" "" 0 "" "" "" "0" "0" "" "" "" "0" "" "" "" NA NA "" NA NA NA "" NA "" "" "" "mut" "" "AML" "case" 3604 3385 3353 7218310.15212442 8 "greater or equal 7" TRUE "U-18-1371" "M" 78 "CITE-seq" "AML-1371" "OSU" "AML1371" "AML" NA "46,XY (17 metas), -Y in 3 metas" 631 "Blasts, defined by CD45 faint staining and low side scatter represent 72.4 % of the total events analyzed and express CD33+, CD117+ and are negative for the remaining markers. " "" "x" "x" "" "" "" NA NA "0" "0,48" "0" "0" "0" 0 "0" "0" "0" "0" "0" "0" "0" "0" "0,42" "0" "0" "0" 0 0 "0" 0 0 0 "0,47" 0 "0" "0" "0" "0" "0" "AML" "case" 3190 3183 3182 8180661.45346835 8 "greater or equal 7" TRUE "U-16-2123" "F" 71 "CITE-seq" "AML-2123" "OSU" "AML2123" "AML" "Intermediate" "46,XX" 1807 "Immunophenotypic analysis demonstrates an abnormal myeloid HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, consistent with acute myeloid leukemia. Correlation with bone marrow morphology and cytogenetic studies is recommended. PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 23.0 % of the total events analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 44.4 % of the total events analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with subpopulation(s) expressing cMPO+ ( 44%) and are negative for the remaining markers analyzed. " "" "" "x" "" "" "" NA NA "0,25" "0" "0" "0" "0" 0 "0" "0" "0" "0" "0" "0" "0" "0" "0" "0" "0" "0" 0 0 "0" 0 0 0 "0" NA "" "" "" "" "" "AML" "case" 1333 1278 1265 2819869.57993261 7 "greater or equal 7" TRUE "U-16-3133" "M" 57 "CITE-seq" "AML-3133" "OSU" "AML3133" "AML" "Favorable" "46,XY[19]/nonclonal[1]" 170 "11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.   SAMPLE TYPE: Bone Marrow LABORATORY INTERPRETATION: Immunophenotypic analysis demonstrates an abnormal myeloid blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers analyzed. The monocytes show aberrant expression of CD56/CD16. " "x" "x" "x" "" "" "" NA NA "0,3" "0" "0" "0" "0" 0 "0" "0,44" "0" "0" "0" "0" "0" "0" "0,44" "0" "0" "0.05 0.08" 0 0 "0" 0 0 0 "0" 0 "0" "0" "0" "0" "0" "AML" "case" 2499 2457 2448 4903210.27518373 8 "greater or equal 7" TRUE "U-18-4340" "M" 80 "CITE-seq" "AML-4340" "OSU" "AML4340" "AML" "Intermediate" "46,XY" 455 "Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 56.7 % of the total events analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). The B cells represent 13.5 % of the lymphocytes (8.0 % of the total events analyzed) and express CD19+, CD20+ bright  with subpopulation(s) expressing CD23+(4%). The B cells are essentially negative for CD10 and CD5. Surface immunoglobulin light chains shows a Kappa:Lambda ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 faint staining and low side scatter represent 19.6 % of the total events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, CD117+, and are negative for the remaining markers analyzed. " "x" "" "x" "" "" "" NA NA "0,37" "0" "0" "0" "0" 0 "0,34" "0" "0" "0" "0" "0" "0" "0" "0" "0" "0,24" "0" 0 0 "0" 0 0 0 "0" 0 "0" "0" "0" "0" "0" "AML" "case" 2800 2793 2787 6733115.22728632 7 "greater or equal 7" TRUE "1" "F" 26 "CITE-Seq" "healthy-1" NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA "healthy" "control" 2995 2964 2832 6251498.79290104 8 "greater or equal 7" TRUE "2" "M" 39 "CITE-Seq" "healthy-2" NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA "healthy" "control" 2489 2476 2399 5431881.0778559 8 "greater or equal 7" TRUE "3" "F" 50 "CITE-Seq" "healthy-3" NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA "healthy" "control" 4008 3986 3963 8805479.48941174 8 "greater or equal 7" TRUE "4" "M" 20 "CITE-Seq" "healthy-4" NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA "healthy" "control" 5858 5833 5540 12561081.5177718 8 "greater or equal 7" TRUE "4003" "M" 42 "CITE-Seq + scTCR-seq" "healthy-4003" NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA "healthy" "control" 6890 6802 6783 14441581.3459165 8 "greater or equal 7" TRUE "5" "M" 47 "CITE-Seq" "healthy-5" NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA "healthy" "control" 4307 3980 3874 7388398.12692058 8 "greater or equal 7" TRUE